Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1609-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.16 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) announced its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.63 EPS. View Shire's Earnings History.
What price target have analysts set for SHPG?
8 brokerages have issued 1-year price objectives for Shire's shares. Their predictions range from $195.00 to $222.00. On average, they anticipate Shire's share price to reach $204.3333 in the next year. View Analyst Price Targets for Shire.
What is the consensus analysts' recommendation for Shire?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Shire.
Has Shire been receiving favorable news coverage?
News articles about SHPG stock have been trending positive recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shire earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Shire.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Zoetis (ZTS), Allergan (AGN) and Vertex Pharmaceuticals (VRTX).
What other stocks do shareholders of Shire own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Walt Disney (DIS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Cisco Systems (CSCO), Netflix (NFLX) and Allergan (AGN).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
How do I buy shares of Shire?
Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Shire?
Shire has a market capitalization of $0.00 and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (NASDAQ SHPG)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
